Revolution Medicines (RVMD) Revenue (2019 - 2023)

Revolution Medicines' Revenue history runs 5 years deep, the most recent figure standing at $742000.0 for Q4 2023.

• On a quarterly basis, Revenue fell 95.16% year-over-year to $742000.0 in Q4 2023; TTM through Sep 2024 was $742000.0, a 97.16% decrease from a year earlier, with the FY2023 full-year figure at $11.6 million, down 67.27% from the prior year.
• Revenue declined to $742000.0 in Q4 2023 per RVMD's latest filing, from $3.8 million in the prior quarter.
• Across five years, Revenue topped out at $15.3 million in Q4 2022 and bottomed at $742000.0 in Q4 2023.
• The 5-year median for Revenue is $9.5 million (2021), against an average of $8.9 million.
• Across the five-year window, Revenue surged 204.81% in 2022 and plunged 95.16% in 2023, its largest moves.
• Year by year, Revenue stood at $12.1 million in 2019, then retreated by 27.61% to $8.8 million in 2020, then advanced by 8.1% to $9.5 million in 2021, then soared by 62.05% to $15.3 million in 2022, then plunged by 95.16% to $742000.0 in 2023.
• Per Business Quant, the three latest RVMD Revenue figures stand at $742000.0 (Q4 2023), $3.8 million (Q2 2023), and $7.0 million (Q1 2023).